

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231



March 11, 2001

In re Application of: Chang  
Serial No.: 09/358,322  
Filed: 7/21/99  
For: EHRLICHIA CANIS GENES AND VACCINES

STATEMENT UNDER 37 CFR § 1.821 (f) & (g)

I hereby state that the content of the paper copy of the Sequence Listing, the copy of the Sequence Listing in computer readable form, and the Statement that the paper copy and the copy in computer readable form are the same, submitted herewith do not contain any new matter as required under 37 CFR § 1.821 (g).


Respectfully submitted,

By: 

Christopher A. Michaels, Reg. No. 34,390  
Attorney for Applicant  
Brown, Pinnisi & Michaels  
400 M&T Bank Building  
118 North Tioga Street  
Ithaca, New York 14850-4343

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as [x] Certified Mail No. 7001 19400001 4327 3341, return receipt requested, in an envelope addressed to the Commissioner of Patent and Trademarks, Washington, D.C. 20231, on March 11, 2002, ~~2001~~.

  
Judy H. Barron



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20230  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/004,494	11/02/2001	Yung-Fu Chang	CRF-2322 CIP

020808  
BROWN PINNISI & MICHAELS  
400 M & T BANK BUILDING  
118 NORTH TIOGA ST  
ITHACA, NY 14850



CONFIRMATION NO. 9399

## FORMALITIES LETTER



\*OC000000007479767\*

Date Mailed: 02/14/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hadlaczký *et al.*

Serial No.: 09/836,911

Filed: April 17, 2001

For: *ARTIFICIAL CHROMOSOMES, USES  
THEREOF AND METHODS FOR PREPARING  
ARTIFICIAL CHROMOSOMES*

CONFIRMATION NO: 7763

Art Unit: 1642

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202, on this date.

03/11/02  
Date

  
Lynn Morkunas

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

Commissioner for Patents  
Arlington, VA 22202

Dear Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed February 5, 2002, and the Raw Sequence Listing Error Report mailed with the Notice to Comply please amend the application as follows:

**IN THE SEQUENCE LISTING:**

Please replace the sequence listing in the above-captioned application with the attached replacement SEQUENCE LISTING. A disk copy of the SEQUENCE LISTING accompanies this response.

**REMARKS**

Attached herewith is a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and the Raw Sequence Listing Error Report mailed on February 5, 2002, paper and disk copy of the replacement Sequence Listing, and a Verified Statement that the content of the paper and computer readable copies are the same. It is believed that no fee is due. However, if it is determined that a fee is due, any fees that may be due in connection with this paper or with this application during its entire pendency may be

USSN 09/836,911

Hadlaczky *et al.*

**RESPONSE TO NOTICE TO COMPLY**

charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

The replacement Sequence Listing differs from the Sequence Listing as originally filed in that the replacement Sequence Listing reflects corrections made in response to the Raw Sequence Listing Error Report supplied with the Notice to Comply, mailed February 5, 2002, as follows:

The General Information section has been amended to include the application number and the filing date. The General Information section has also been amended to list the Prior Application Data under item number (vii) instead of item number (vi);

In SEQ ID NOS. 1-34, under item number (iv), the word "ANTISENSE" has been replaced with —ANTI-SENSE—; and

In SEQ ID NO. 9, the amino acid numbering has been added.

These corrections are formal and responsive to the Raw Sequence Listing Error Report and the Notice to Comply mailed February 5, 2002, and thus no new matter has been added.

\* \* \*

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 24601-4021

**Address all correspondence to:**

Heller Ehrman White & McAuliffe LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, California 92122-1246

Telephone: (858)450-8400

Facsimile: (858)587-5360

EMAIL: sseidman@HEWM.com